Cancer immunotherapy: The past, the present and the future

Immunology and Cell Biology

Volumn 81, Issue 2, 2003, Pages 106-113

  Parish, Christopher R ^a  

^a Biology and Environment   (Australia)

Author keywords

Adaptive immunity; Cancer immunotherapy; Immune evasion; Immunosurveillance; Innate immunity

Indexed keywords

BONE MARROW CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HISTORY; HYPOXIA; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; REVIEW; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; NEOPLASMS;

EID: 0037383526     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0818-9641.2003.01151.x     Document Type: Review

References (101)

1. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 1994; 64: 529-64.
2. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 1893; 105: 487-511.
3. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 1909; 5: 273-90.
4. Woglom WH. Immunity to transplantable tumours. Cancer Res. 1929; 4: 129-38.
5. Kamat AM, Lamm DL. Immunotherapy for bladder cancer. Curr. Urol. Rep. 2001; 2: 62-9.
6. Bassi P. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg. Oncol. 2002; 11: 77-83.
7. Burnet FM, Fenner F, eds. The Production of Antibodies. London: Macmillan, 1949.
8. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603-6.
9. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953; 13: 835-7.
10. Baldwin RW. Immunity to methylcholanthrene-induced tumors in inbred rats following atrophy and regression of implanted tumors. Br. J. Cancer 1955; 9: 652-65.
11. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 1957; 18: 769-78.
12. Klein G, Sjogren HO, Klein E, Hellström KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960; 20: 1561-72.
13. Burnet FM. Immunological aspects of malignant disease. Lancet 1967; 1: 1171-4.
14. Thomas L. Discussion of cellular and humoral aspects of the hypersensitivity states. In: Lawrence HS, ed. Cellular and Humoral Aspects of Hypersensitivity. New York: Hoeber-Harper, 1959; 529-32.
15. Stutman O. Spontaneous tumors in nude mice: effect of the viable yellow gene. Exp. Cell Biol. 1979; 47: 129-35.
16. Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J. Natl. Cancer Inst. 1979; 62: 353-8.
17. Stutman O. Immunodepression and malignancy. Adv. Cancer Res. 1975; 22: 261-422.
18. Maleckar JR, Sherman LA. The composition of the T cell receptor repertoire in nude mice. J. Immunol. 1987; 138: 3873-6.
19. Zinkernagel RM. Thymus and lymphohemopoietic cells: their role in T cell maturation in selection of T cells' H-2-restriction-specificity and in H-2 linked Ir gene control. Immunol. Rev. 1978; 42: 224-70.
20. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells. Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 1979; 27: 51-177.
21. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 1976; 33: 241-59.
22. Arnold B, Schonrich G, Hammerling GJ. Multiple levels of peripheral tolerance. Immunol. Today 1993; 14: 12-14.
23. Fowlkes BJ, Ramsdell F. T-cell tolerance. Curr. Opin. Immunol. 1993; 5: 873-9.
24. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994; 12: 991-1045.
25. Urban JL, Schreiber H. Tumor antigens. Annu. Rev. Immunol. 1992; 10: 617-44.
26. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994; 12: 337-65.
27. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 1996; 183: 725-9.
28. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7.
29. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv. Immunol. 2000; 75: 235-82.
30. Fenton RG, Longo DL. Genetic instability and tumor cell variation: implications for immunotherapy. J. Natl. Cancer Inst. 1995; 87: 241-3.
31. Stoler DL, Chen N, Basik M et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl Acad. Sci. USA 1999; 96: 15121-6.
32. Steinman RM, Young JW. Signals arising from antigen-presenting cells. Curr. Opin. Immunol. 1991; 3: 361-72.
33. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065-8.
34. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261-82.
35. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995; 270: 932-3.
36. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 1998; 95: 1178-83.
37. Baxter AG, Hodgkin PD. Activation rules: the two-signal theories of immune activation. Nat. Rev. Immunol. 2002; 2: 439-46.
38. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 1994; 24: 605-10.
39. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995; 1: 1297-302.
40. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 1996; 183: 283-7.
41. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp. Hematol. 2001; 29: 1247-55.
42. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 2001; 94: 459-73.
43. Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. 2002; 94: 805-18.
44. Byrne SN, Halliday GM. Dendritic cells: Making progress with tumour regression? Immunol. Cell Biol. 2002; 80: 520-30.
45. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
46. van den Broek ME, Kagi D, Ossendorp F et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 1996; 184: 1781-90.
47. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 2000; 192: 755-60.
48. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 1998; 95: 7556-61.
49. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1: 447-56.
50. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2001; 2: 293-9.
51. Smyth MJ, Thia KY, Street SE et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000; 191: 661-8.
52. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-71.
53. Lanier LL. A renaissance for the tumor immunosurveillance hypothesis. Nat. Med. 2001; 7: 1178-80.
54. Girardi M, Oppenheim DE, Steele CR et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294: 605-9.
55. Parish CR, O'Neill ER. Dependence of the adaptive immune response on innate immunity: some questions answered but new paradoxes emerge. Immunol. Cell Biol. 1997; 75: 523-7.
56. Hobohm U. Fever and cancer in perspective. Cancer Immunol. Immunother. 2001; 50: 391-6.
57. Yamamoto S, Yamamoto T, Shimada S et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. 1992; 36: 983-97.
58. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 1992; 148: 4072-6.
59. Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity 1996; 5: 303-10.
60. Medzhitov R, Janeway C Jr. The Toll receptor family and microbial recognition. Trends Microbiol. 2000; 8: 452-6.
61. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001; 2: 675-80.
62. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989; 54 Part 1: 1-13.
63. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 1992; 13: 11-16.
64. Janeway CA Jr, Goodnow CC, Medzhitov R. Danger - pathogen on the premises! Immunological tolerance. Curr. Biol. 1996; 6: 519-22.
65. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272: 50-3.
66. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin. Immunol. 1996; 8: 271-80.
67. Groh V, Bahram S, Bauer S, Herman A, Beuchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class 1 gene expressed in gastrointestinal epithelium. Proc. Natl Acad. Sci. USA 1996; 93: 12445-50.
68. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 1999; 96: 6879-84.
69. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2001; 2: 255-60.
70. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
71. Cerwenka A, Bakker AB, McClanahan T et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000; 12: 721-7.
72. Cosman D, Mullberg J, Sutherland CL et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-33.
73. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 1990; 82: 4-6.
74. Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. J. Pathol. 1996; 179: 232-7.
75. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
76. Zetter BR. Angiogenesis and tumor metastasis. Annu. Rev. Med. 1998; 49: 407-24.
77. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000; 74: 181-273.
78. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 1999; 5: 178-86.
79. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 1998; 64: 275-90.
80. Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 1998; 10: 564-72.
81. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 1996; 19: 81-4.
82. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 2000; 191: 795-804.
83. Cavanagh LL, Von Andrian UH. Travellers in many guises: The origins and destinations of dendritic cells. Immunol. Cell Biol. 2002; 80: 448-62.
84. Belz GT, Heath WR, Carbone FR. The role of dendritic cell subsets in selection between tolerance and immunity. Immunol. Cell Biol. 2002; 80: 463-8.
85. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell Biol. 2002; 80: 477-83.
86. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 1995; 7: 529-34.
87. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-9.
88. Kern DE, Klarnet JP, Jensen MC, Greenberg PD. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol. 1986; 136: 4303-10.
89. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 1998; 187: 693-702.
90. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 1998; 4: 627-30.
91. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4 (+) T cells in the antitumor immune response. J. Exp. Med. 1998; 188: 2357-68.
92. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 1999; 190: 617-27.
93. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-12.
94. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257: 548-51.
95. Volpert OV, Fong T, Koch AE et al. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 1998; 188: 1039-46.
96. Mattes J, Hulett M, Xie W et al. Immunotherapy of cytotoxic T cell resistant tumors by T helper 2 cells: an eotaxin and STAT6 dependent process. J. Exp. Med. 2003; 197: 387-93.
97. Rothenberg ME. Eotaxin: An essential mediator of eosinophil trafficking into mucosal tissues. Am. J. Respir. Cell Mol. Biol. 1999; 21: 291-5.
98. Crowther M, Brown NJ, Bishop ET, Lewis CE. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J. Leukoc. Biol. 2001; 70: 478-90.
99. Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 1999; 43: S69-71.
100. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996; 56: 4625-9.
101. Disis ML, Schiffman K. Issues on clinical applications of cancer vaccines. J. Immunother. 2001; 24: 104-5.